Icon times
Strong traction in India and the US market and launches of new products including Revlimid aided the growth in revenue however rise in cost eroded Margins | Zydus Lifesciences Q2 FY23 Result & Earning Call Highlights
Back
  • Home
  • Articles
  • Strong traction in India and the US market and launches of new products including Revlimid aided the growth in revenue however rise in cost eroded Margins | Zydus Lifesciences Q2 FY23 Result & Earning Call Highlights

Strong traction in India and the US market and launches of new products including Revlimid aided the growth in revenue however rise in cost eroded Margins | Zydus Lifesciences Q2 FY23 Result & Earning Call Highlights

Published on 15 November 2022 .Views 17 .Comments 0
Methodology Video
Share On
Please find attached for detailed analysis.
Attachments:
Tags:
#Q2 FY23 Result Analysis
#Earning Calls
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 11,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded


premium Premium
free Free
View All
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya